Bio-Plex^® Multiplex Assays

In December 2022, a groundbreaking law was passed granting the U.S. FDA the authority to consider data from new alternative methods in the preclinical testing phase for new drug development. Among the new methods are 3D cell cultures that mimic human tissues and organs, known as microphysiological systems (MPS). The new law aims to improve clinical outcomes while decreasing reliance on animal testing. In this article, we discuss MPS and review data showing how they can synergize with Bio-Plex Assays.

In this webinar, see how a Bio-Plex Pro Assay could provide a high-throughput culture-free NT50 determination method for current and future SARS-CoV-2 variants.